2021年12月21日

分享轨道健康,一个德国的数字健康启动时,宣布投资100万€从医学技术企业家(MTE)的加速增长。去年赢得EIT健康外卡的挑战后,轨道进一步获得世界先导研究所基金会的支持(BII)和行业顾问。MTE最新投资的轨道实现€400万年总资金加快企业的发展对其目标个性化照顾帕金森氏症和其他慢性疾病通过数字医疗创新方面有所突破。超过1000万人患有帕金森症,但每一个人经历不同的症状,对治疗的反应是不同的。轨道上健康的旗舰“海王星”解决方案帮助帕金森患者的症状控制最大化。它利用了人工智能的力量与利用只有smartwatch启用个性化治疗,这是恳切地需要持续的帕金森症护理。“医疗的未来是数字的,尤其是在快速增长的慢性疾病空间。这就是为什么MTE重点投资于有前途的医学技术和数字健康创业和设置他们的成功与我们的巨大的行业专业知识和广泛的网络,“管理合伙人MTE杜米尼克摩尔说。“我们兴奋地投资于轨道。强大的团队,一个清晰的焦点,和优秀的产品市场健康,轨道不仅加强了我们的投资组合,但也增强了我们的能力来支持高潜力的创业HealthTech变换医疗任务。” To further deliver comprehensive patient insights and address the increasing threat of multiple chronic diseases, Orbit is enriching its solution by bringing together hundreds of relevant health and wellness data points including insights from common monitoring solutions such as blood pressure monitoring systems and glucose meters from siloed environments and integrating them with medical-grade, clinically validated digital health tools. The aim is to streamline the adoption and orchestration of novel digital health solutions and integrate them into the routine clinical workflows to achieve holistic patient care and real impact. “We are excited to further strengthen Orbit with MTE’s support and be part of their vibrant ecosystem. ‘Neptune’ is a great example of how chronic diseases can be managed and in the future. It not only offers healthcare professionals the necessary insights to effectively personalize treatments and deliver timely interventions, but it also empowers patients to take better control of their conditions and to live life confidently,” said Patty Lee , CEO & Co-founder of Orbit Health. “We see remote personalized care powered by digital health and biomarker solutions as a way forward for chronic care because every patient is different, and a 24/7 condition deserves a 24/7 solution.” “At least one in three adults has more than one chronic disease. Physicians are currently relying on only a snapshot of information to make treatment decisions. This makes the personalization of long-term care a huge challenge,” said Werner Boeing , former CIO of Roche Diagnostics and currently CEO & Co-founder of Evisory and Orbit Health advisor. “Digital biomarker solutions like Orbit’s Neptune can be the new pillar of diagnostics to address chronic disease burden and the ever-changing healthcare demand. I am extremely happy to see the progress Orbit has made thus far and look forward to continue to support them in their exciting journey ahead.”